Biomarin Pharmaceutical (BMRN) Enterprise Value (2016 - 2025)
Biomarin Pharmaceutical (BMRN) has disclosed Enterprise Value for 17 consecutive years, with -$1.6 billion as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Enterprise Value fell 37.17% year-over-year to -$1.6 billion, compared with a TTM value of -$1.6 billion through Dec 2025, down 37.17%, and an annual FY2025 reading of -$1.6 billion, down 37.17% over the prior year.
- Enterprise Value was -$1.6 billion for Q4 2025 at Biomarin Pharmaceutical, down from -$1.5 billion in the prior quarter.
- Across five years, Enterprise Value topped out at -$930.4 million in Q3 2024 and bottomed at -$1.6 billion in Q4 2025.
- Average Enterprise Value over 5 years is -$1.2 billion, with a median of -$1.1 billion recorded in 2023.
- The sharpest move saw Enterprise Value rose 28.31% in 2021, then tumbled 58.83% in 2025.
- Year by year, Enterprise Value stood at -$1.0 billion in 2021, then dropped by 27.39% to -$1.3 billion in 2022, then increased by 16.86% to -$1.1 billion in 2023, then fell by 5.95% to -$1.1 billion in 2024, then crashed by 37.17% to -$1.6 billion in 2025.
- Business Quant data shows Enterprise Value for BMRN at -$1.6 billion in Q4 2025, -$1.5 billion in Q3 2025, and -$1.4 billion in Q2 2025.